Relationship of tafamidis binding site occupancy, transthyretin stabilization, and disease modification in tafamidis treated transthyretin amyloid cardiomyopathy patients
Event:
ESC Congress 2022
Topic:
Pharmacotherapy
Session:
Chronic heart failure - Amyloidosis